Treatment Compliance in Children and Adolescents on ADHD Medication

Eli Lilly and Company518 enrolled

Overview

The primary research objective of this observational study is to evaluate treatment compliance over one year in children and adolescents who are newly initiated on medication approved for the treatment of ADHD in a routine clinical setting. Compliance will be assessed using the Pediatric Compliance Self-Rating (PCSR) Instrument. A patient will be considered as compliant at a given visit, if the PCSR score is at least 5, corresponding to taking the medication at least often.

Study Type

OBSERVATIONAL

Enrollment

518

Conditions

ADHD

Interventions

AtomoxetineDRUG

in-label use

stimulants (any approved ADHD medication)DRUG

in-label use

Eligibility

Sex: ALLMin age: 6 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 6-17 years old * diagnosis of ADHD according to ICD-10 or DSM-IV criteria * new initiation onto an approved medication to treat ADHD Exclusion Criteria: * no specific exclusion criteria

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Bad Homburg, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.